These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 26950278)

  • 21. Association of HMGCR polymorphism with late-onset Alzheimer's disease in Han Chinese.
    Chang XL; Tan L; Tan MS; Wang HF; Tan CC; Zhang W; Zheng ZJ; Kong LL; Wang ZX; Jiang T; Yu JT; Tan L
    Oncotarget; 2016 Apr; 7(16):22746-51. PubMed ID: 27009838
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluating the association between brain atrophy, hypometabolism, and cognitive decline in Alzheimer's disease: a PET/MRI study.
    Chen Y; Wang J; Cui C; Su Y; Jing D; Wu L; Liang P; Liang Z
    Aging (Albany NY); 2021 Feb; 13(5):7228-7246. PubMed ID: 33640881
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potential neuroimaging biomarkers of pathologic brain changes in Mild Cognitive Impairment and Alzheimer's disease: a systematic review.
    Ruan Q; D'Onofrio G; Sancarlo D; Bao Z; Greco A; Yu Z
    BMC Geriatr; 2016 May; 16():104. PubMed ID: 27184250
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease.
    Kerbler GM; Fripp J; Rowe CC; Villemagne VL; Salvado O; Rose S; Coulson EJ;
    Neuroimage Clin; 2015; 7():105-13. PubMed ID: 25610772
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structural Neuroimaging Genetics Interactions in Alzheimer's Disease.
    Moon SW; Dinov ID; Kim J; Zamanyan A; Hobel S; Thompson PM; Toga AW
    J Alzheimers Dis; 2015; 48(4):1051-63. PubMed ID: 26444770
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of EPHA1 genetic variation on cerebrospinal fluid and neuroimaging biomarkers in healthy, mild cognitive impairment and Alzheimer's disease cohorts.
    Wang HF; Tan L; Hao XK; Jiang T; Tan MS; Liu Y; Zhang DQ; Yu JT;
    J Alzheimers Dis; 2015; 44(1):115-23. PubMed ID: 25182741
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The hydroxy-methyl-glutaryl CoA reductase promoter polymorphism is associated with Alzheimer's risk and cognitive deterioration.
    Porcellini E; Calabrese E; Guerini F; Govoni M; Chiappelli M; Tumini E; Morgan K; Chappell S; Kalsheker N; Franceschi M; Licastro F
    Neurosci Lett; 2007 Apr; 416(1):66-70. PubMed ID: 17284348
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic study of multimodal imaging Alzheimer's disease progression score implicates novel loci.
    Scelsi MA; Khan RR; Lorenzi M; Christopher L; Greicius MD; Schott JM; Ourselin S; Altmann A
    Brain; 2018 Jul; 141(7):2167-2180. PubMed ID: 29860282
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low LDL cholesterol,
    Benn M; Nordestgaard BG; Frikke-Schmidt R; Tybjærg-Hansen A
    BMJ; 2017 Apr; 357():j1648. PubMed ID: 28438747
    [No Abstract]   [Full Text] [Related]  

  • 30. Dynamics of brain structure and cognitive function in the Alzheimer's disease neuroimaging initiative.
    Song X; Mitnitski A; Zhang N; Chen W; Rockwood K;
    J Neurol Neurosurg Psychiatry; 2013 Jan; 84(1):71-8. PubMed ID: 23123510
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Longitudinal Neuroimaging Hippocampal Markers for Diagnosing Alzheimer's Disease.
    Platero C; Lin L; Tobar MC
    Neuroinformatics; 2019 Jan; 17(1):43-61. PubMed ID: 29785624
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predicting the progression of mild cognitive impairment to Alzheimer's disease by longitudinal magnetic resonance imaging-based dictionary learning.
    Lin Y; Huang K; Xu H; Qiao Z; Cai S; Wang Y; Huang L;
    Clin Neurophysiol; 2020 Oct; 131(10):2429-2439. PubMed ID: 32829290
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Single time point high-dimensional morphometry in Alzheimer's disease: group statistics on longitudinally acquired data.
    Duchesne S; Valdivia F; Mouiha A; Robitaille N;
    Neurobiol Aging; 2015 Jan; 36 Suppl 1():S11-22. PubMed ID: 25444598
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
    Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
    Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lower Serum Calcium as a Potentially Associated Factor for Conversion of Mild Cognitive Impairment to Early Alzheimer's Disease in the Japanese Alzheimer's Disease Neuroimaging Initiative.
    Sato K; Mano T; Ihara R; Suzuki K; Tomita N; Arai H; Ishii K; Senda M; Ito K; Ikeuchi T; Kuwano R; Matsuda H; Iwatsubo T; Toda T; Iwata A;
    J Alzheimers Dis; 2019; 68(2):777-788. PubMed ID: 30814351
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer's Disease Neuroimaging Initiative (ADNI) CSF.
    Spellman DS; Wildsmith KR; Honigberg LA; Tuefferd M; Baker D; Raghavan N; Nairn AC; Croteau P; Schirm M; Allard R; Lamontagne J; Chelsky D; Hoffmann S; Potter WZ; ;
    Proteomics Clin Appl; 2015 Aug; 9(7-8):715-31. PubMed ID: 25676562
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Visualizing modules of coordinated structural brain atrophy during the course of conversion to Alzheimer's disease by applying methodology from gene co-expression analysis.
    Sato K; Mano T; Matsuda H; Senda M; Ihara R; Suzuki K; Arai H; Ishii K; Ito K; Ikeuchi T; Kuwano R; Toda T; Iwatsubo T; Iwata A;
    Neuroimage Clin; 2019; 24():101957. PubMed ID: 31400633
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improved multimodal prediction of progression from MCI to Alzheimer's disease combining genetics with quantitative brain MRI and cognitive measures.
    Reas ET; Shadrin A; Frei O; Motazedi E; McEvoy L; Bahrami S; van der Meer D; Makowski C; Loughnan R; Wang X; Broce I; Banks SJ; Fominykh V; Cheng W; Holland D; Smeland OB; Seibert T; Selbaek G; Brewer JB; Fan CC; Andreassen OA; Dale AM;
    Alzheimers Dement; 2023 Nov; 19(11):5151-5158. PubMed ID: 37132098
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Feasibility and acceptance of simultaneous amyloid PET/MRI.
    Schütz L; Lobsien D; Fritzsch D; Tiepolt S; Werner P; Schroeter ML; Berrouschot J; Saur D; Hesse S; Jochimsen T; Rullmann M; Sattler B; Patt M; Gertz HJ; Villringer A; Claßen J; Hoffmann KT; Sabri O; Barthel H
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2236-2243. PubMed ID: 27435367
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cognitive and neuroimaging profiles in mild cognitive impairment and Alzheimer's disease: data from the Spanish Multicenter Normative Studies (NEURONORMA Project).
    Sánchez-Benavides G; Peña-Casanova J; Casals-Coll M; Gramunt N; Molinuevo JL; Gómez-Ansón B; Aguilar M; Robles A; Antúnez C; Martínez-Parra C; Frank-García A; Fernández-Martínez M; Blesa R;
    J Alzheimers Dis; 2014; 41(3):887-901. PubMed ID: 24718100
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.